Docoh
Loading...

GSK Glaxosmithkline

Filed: 27 Nov 20, 10:20am
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of November 2020
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 


 
GlaxoSmithKline plc
 
GSK publishes provisional dividend dates
 
 
GSK announces the following dividend dates for 2021:
 
 
 Results
 
Announcement dateEx-dividend dateRecord dateLast date for DRIP electionsPayable
Q1 2021Wednesday 28 April 2021Thursday 20 May 2021Friday 21 May 2021
 
Thursday 17 June 2021
 
Thursday 8 July 2021
 
Q2 2021
 
Wednesday 28 July 2021Thursday 19 August 2021Friday 20 August 2021Thursday 16 September 2021Thursday 7 October 2021
 
Q3 2021
 
Wednesday 27 October 2021Thursday 18 November 2021Friday 19 November 2021Monday 20 December 2021Thursday 13 January 2022
 Q4 2021
(Final)
Wednesday 9 February 2022Thursday 24 February 2022Friday 25 February 2022Thursday 17 March 2022
 
Thursday 7 April 2022
 
 
These dates are indicative and may be subject to change.  
 
 
 
 
V A Whyte
Company Secretary
 
27 November 2020
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 GlaxoSmithKline plc
 (Registrant)
  
Date: November 27, 2020 
  
 
By:/s/ VICTORIA WHYTE
--------------------------
  
 Victoria Whyte
 Authorised Signatory for and on
 behalf of GlaxoSmithKline plc